As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?
İzzet Tandoğan1Department of Cardiology Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?
İzzet Tandoğan1Department of Cardiology Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
İzzet Tandoğan. Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anatol J Cardiol. 2007; 7(2): 216-216 Manuscript Language: English